 We've been working very closely with the transplant group here at the John Torre Cancer Center to look at the effects of checkpoint inhibitors that are being used to treat patients with leukemia, lymphoma, and multiple myeloma, and to see how those drugs are actually affecting the immune system, the reconstitution after a transplant, and whether they're generating as they should. I feel that we are hoping to understand new therapies that are being developed, new immunotherapies, and how they interact with the immune system of the patients, how they affect them. That this is important for improving the overall outcomes for treating these diseases.